Dopamine and glutamate in Huntington's disease: A balancing act.
about
The importance of integrating basic and clinical research toward the development of new therapies for Huntington diseaseEvidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of NeurologyCentral Role of Glutamate Metabolism in the Maintenance of Nitrogen Homeostasis in Normal and Hyperammonemic BrainMouse models of polyglutamine diseases: review and data table. Part IStriatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicityRoles of cocaine- and amphetamine-regulated transcript in the central nervous systemReview: Modulation of striatal neuron activity by cyclic nucleotide signaling and phosphodiesterase inhibitionThe Chemistry of Neurodegeneration: Kinetic Data and Their Implications.Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity.Therapeutic advances in Huntington's Disease.Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxiasStriatal pre-enkephalin overexpression improves Huntington's disease symptoms in the R6/2 mouse model of Huntington's diseaseNeural tissue engineering using embryonic and induced pluripotent stem cells.Brief mitochondrial inhibition causes lasting changes in motor behavior and corticostriatal synaptic physiology in the Fischer 344 rat.The Spectrum of Psychiatric Pathology in a Patient with Genetically Verified Huntington's Disease.Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.Biological sources of inflexibility in brain and behavior with aging and neurodegenerative diseases.The BMP signaling pathway at the Drosophila neuromuscular junction and its links to neurodegenerative diseases.Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence.The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation.Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington's disease.Challenges of Huntington's disease and quest for therapeutic biomarkers.Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine ModulationAssociation of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.Ceftriaxone increases glutamate uptake and reduces striatal tyrosine hydroxylase loss in 6-OHDA Parkinson's model.Dissecting the contribution of individual receptor subunits to the enhancement of N-methyl-d-aspartate currents by dopamine D1 receptor activation in striatumPreserving cortico-striatal function: deep brain stimulation in Huntington's disease.Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.Ameliorating effect of Celastrus paniculatus standardized extract and its fractions on 3-nitropropionic acid induced neuronal damage in rats: possible antioxidant mechanism.Functional increase of brain histaminergic signaling in Huntington's disease.Combined lesions of direct and indirect basal ganglia pathways but not changes in dopamine levels explain learning deficits in patients with Huntington's disease.Glutamate excitotoxicity activates the MAPK/ERK signaling pathway and induces the survival of rat hippocampal neurons in vivo.
P2860
Q22306292-695F6692-F8D3-4CD2-8784-E198D8425826Q24621818-5B0D2E38-08E3-49F2-A863-BA66A7076061Q26749567-9A974618-19BC-493E-8D2C-CE593C804B91Q26853025-06BFF0CB-BE55-4591-84D6-FB6611BAAB3BQ28239309-42B47895-927D-47DC-A13C-4A962505D9A5Q28252842-F596C17B-6448-4C74-B040-880993AE151CQ28394979-99DB5402-0602-4E06-8F10-50AFCA8CD26EQ30973484-68C93E34-8116-469E-9350-9564A28D5A1CQ33831774-39241AF0-80C4-46F9-828D-0F98FFD3D6EAQ34310129-6D8C865B-4936-476C-8168-BFC406441824Q34487604-C49E6584-E443-4279-B7D4-C52DC88E1980Q34547558-D3FFBB63-044D-48C9-BA27-0A86E2BC5C7AQ34981549-2C34425F-EAD4-4CCD-9774-3BD6C0751F76Q34990529-F4152098-297B-4565-8615-F8945AC4B3F4Q35579271-B1BEE8A2-5D79-4D3C-A65D-DCFF18EF3466Q36019780-2D8FC26C-A650-4AE1-9B81-B37DF2F83890Q36106163-1202223B-45F6-4277-9A21-E651D5565D20Q36316344-2C8BF1FB-113B-416D-B170-D673D712C8F8Q36434965-B12C9D7F-DD7C-4FE3-B064-E6F886D309D5Q37787429-5FB266AE-B3FF-4022-AFFD-1514F428F2D6Q37930190-9212DC9D-C27E-4E56-BBB5-73F8FF4BA4C0Q38035863-AD98DD4B-A9E9-41C7-9F98-47019BC7EF47Q38168592-444979CD-A706-4C69-83B1-16046B4C0602Q38206500-DC7EA906-4A74-4927-BBCC-0B3FA1DAA0A2Q38239515-8ACC378E-0F91-402D-A369-1BCE3434256DQ38257697-81B816A7-03B1-4054-BA42-2CC1CB3DDC74Q38603960-C8F711AB-42B9-4E1D-8716-D9F1DE70E662Q38861728-C68623D4-1F07-44E3-9E4D-F0E55A607E85Q39041217-349E9701-ED93-4EAD-8C23-07E47518E9A7Q39079841-B3284989-A987-4D6F-912B-52F11DBF1967Q41911647-0DFBAA30-1E46-4A78-8A8D-BB3C590BF990Q42734818-95ECBC30-F9EA-43F0-A496-160A853F5251Q43182909-88B829DA-E429-456F-A96A-384E59A0E5AAQ45289206-CF3DFA45-157A-435D-A21E-DBA2BCDF3E4BQ45292205-C43E3259-E4B2-4E71-940B-A0D1C06EFF46Q45292629-8E52468C-A99F-41D3-A9FA-5A24B3CE9877Q45300396-EBAF1C95-ADC7-4E81-B533-E4AB29C4906AQ45300658-257D969D-19AF-4317-B9CF-476864FC6D9DQ45304822-8ED0F861-E8E9-4D88-BB24-C24A9172BA8BQ46181611-AC6A1063-1278-451A-9D7B-333C16EBC913
P2860
Dopamine and glutamate in Huntington's disease: A balancing act.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dopamine and glutamate in Huntington's disease: A balancing act.
@en
Dopamine and glutamate in Huntington's disease: A balancing act.
@nl
type
label
Dopamine and glutamate in Huntington's disease: A balancing act.
@en
Dopamine and glutamate in Huntington's disease: A balancing act.
@nl
prefLabel
Dopamine and glutamate in Huntington's disease: A balancing act.
@en
Dopamine and glutamate in Huntington's disease: A balancing act.
@nl
P2093
P2860
P1476
Dopamine and glutamate in Huntington's disease: A balancing act.
@en
P2093
Carlos Cepeda
Michael S Levine
Véronique M André
P2860
P304
P356
10.1111/J.1755-5949.2010.00134.X
P577
2010-04-08T00:00:00Z